199 related articles for article (PubMed ID: 33415792)
21. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
[TBL] [Abstract][Full Text] [Related]
22. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
Chirindel A; Chaudhry M; Blakeley JO; Wahl R
J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
[TBL] [Abstract][Full Text] [Related]
24. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
25. Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals.
Mantripragada KK; Caley M; Stephens P; Jones CJ; Kluwe L; Guha A; Mautner V; Upadhyaya M
Genes Chromosomes Cancer; 2008 Mar; 47(3):238-46. PubMed ID: 18069666
[TBL] [Abstract][Full Text] [Related]
26. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.
Moharir M; London K; Howman-Giles R; North K
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1309-17. PubMed ID: 20179923
[TBL] [Abstract][Full Text] [Related]
27. Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Morphological and Immunohistochemical Study.
Friedrich RE; Nörnberg LKN; Hagel C
Anticancer Res; 2022 Mar; 42(3):1247-1261. PubMed ID: 35220215
[TBL] [Abstract][Full Text] [Related]
28. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
Benz MR; Czernin J; Dry SM; Tap WD; Allen-Auerbach MS; Elashoff D; Phelps ME; Weber WA; Eilber FC
Cancer; 2010 Jan; 116(2):451-8. PubMed ID: 19924789
[TBL] [Abstract][Full Text] [Related]
29. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
[TBL] [Abstract][Full Text] [Related]
30. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
[TBL] [Abstract][Full Text] [Related]
31. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions.
Zhou H; Coffin CM; Perkins SL; Tripp SR; Liew M; Viskochil DH
Am J Surg Pathol; 2003 Oct; 27(10):1337-45. PubMed ID: 14508395
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of
Geitenbeek RTJ; Martin E; Graven LH; Broen MPG; Anten MHME; van der Pol JAJ; Verhoef C; Taal W
J Neurooncol; 2022 Feb; 156(3):559-567. PubMed ID: 35025020
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.
Cardona S; Schwarzbach M; Hinz U; Dimitrakopoulou-Strauss A; Attigah N; Mechtersheimer section sign G; Lehnert T
Eur J Surg Oncol; 2003 Aug; 29(6):536-41. PubMed ID: 12875862
[TBL] [Abstract][Full Text] [Related]
34. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1.
Friedrich RE; Keiner D; Hagel C
Anticancer Res; 2007; 27(4A):2085-90. PubMed ID: 17649826
[TBL] [Abstract][Full Text] [Related]
35. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children.
Friedrich RE; Hartmann M; Mautner VF
Anticancer Res; 2007; 27(4A):1957-60. PubMed ID: 17649804
[TBL] [Abstract][Full Text] [Related]
36. The Role of [
Tovmassian D; Abdul Razak M; London K
Int J Surg Oncol; 2016; 2016():6162182. PubMed ID: 28058117
[No Abstract] [Full Text] [Related]
37. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
Salamon J; Derlin T; Bannas P; Busch JD; Herrmann J; Bockhorn M; Hagel C; Friedrich RE; Adam G; Mautner VF
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
[TBL] [Abstract][Full Text] [Related]
38. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
[TBL] [Abstract][Full Text] [Related]
40. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.
Higham CS; Dombi E; Rogiers A; Bhaumik S; Pans S; Connor SEJ; Miettinen M; Sciot R; Tirabosco R; Brems H; Baldwin A; Legius E; Widemann BC; Ferner RE
Neuro Oncol; 2018 May; 20(6):818-825. PubMed ID: 29409029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
